EGFR and cancer: Pathway analysis of decreased H3K27ac sites revealed an enrichment of ErbB and PI3K-Akt signaling, pathways in cancer, along with ECM-receptor interaction, focal adhesion, and proteoglycans in cancer (Figure 7I).